Revance Therapeutics, Inc.

303 articles about Revance Therapeutics, Inc.

• Revance to Participate in the Cowen 42nd Annual Health Care Conference

  3/2/2022

  Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference.

• Revance Reports Fourth Quarter and Full Year 2021 Financial Results, Provides Corporate Update

  2/28/2022

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

• Revance to Release Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022

  2/22/2022

  Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release fourth quarter and full year 2021 financial results on Monday, February 28, 2022 after the close of market.

• Revance Receives Clarity on Path to Resubmission of the BLA for DaxibotulinumtoxinA for Injection Following Type A Meeting with FDA

  1/18/2022

  Revance Therapeutics, Inc. (Nasdaq: RVNC), a commercial stage biotechnology company focused on innovative aesthetic and therapeutic offerings, announced today that it has received the official Type A meeting minutes from the U.S. Food and Drug Administration (FDA) regarding the Complete Response Letter (CRL) received for DaxibotulinumtoxinA for Injection for glabellar lines.

• Revance Provides Preliminary Fourth Quarter and Full Year 2021 Financial Results and a Corporate Update

  1/7/2022

  Revance Therapeutics, Inc. today provided preliminary fourth quarter and full year 2021 financial results and a corporate update.

• Revance to Present Clinical Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Filler Injection Technique at the 2021 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting

  11/19/2021

  Revance Therapeutics, Inc. today announced two oral presentations and one ePoster at the American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, November 19-21, 2021.

• Revance to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

  11/18/2021

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company’s Chief Executive Officer, Mark Foley, and Chief Financial Officer, Tobin Schilke, will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

• Revance to Participate in the Stifel 2021 Virtual Healthcare Conference

  11/10/2021

  Revance Therapeutics, Inc. today announced that the company will participate in the Stifel 2021 Virtual Healthcare Conference, a fully virtual management access conference, taking place November 15-17.

• Revance Reports Third Quarter 2021 Financial Results, Provides Corporate Update

  11/9/2021

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

• Revance to Release Third Quarter 2021 Financial Results on Tuesday, November 9, 2021

  11/2/2021

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will release third quarter 2021 financial results on Tuesday, November 9, 2021 after the close of market.

• 

  FDA Serves Omeros, MannKind-United and Revance with CRLs

  10/18/2021

  Omeros Corporation shares were down in premarket trading after the company received a CRL for its experimental hematopoietic stem cell transplant-associated thrombotic microangiopathy treatment.

• Revance Provides Regulatory Update on DaxibotulinumtoxinA for Injection for the Treatment of Moderate to Severe Glabellar (Frown) Lines

  10/15/2021

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the United States Food and Drug Administration has issued a Complete Response Letter, or CRL, regarding the Biologics License Application for DaxibotulinumtoxinA for Injection, for the treatment of moderate to severe glabellar lines.

• Revance Continues to Anticipate FDA Approval of DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines in 2021

  10/12/2021

  Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, responds to the public disclosure of its Form 483 pursuant to a Freedom of Information Act (FOIA) request that was directed to the FDA.

• Revance Announces the Launch of OPUL™, the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices

  10/11/2021

  Revance Announces the Launch of OPUL ™ , the First-of-its-Kind Relational Commerce Platform for Aesthetic Practices

• Revance to Showcase Data from Phase 3 ASPEN-1 Clinical Trial Evaluating Efficacy

  9/16/2021

  Revance Therapeutics, Inc. today announced that it will present an ePoster with a video poster presentation by Dr. Joseph Jankovic at the International Parkinson and Movement Disorder Society (MDS) Virtual Congress 2021 taking place from September 17-22, 2021.

• Revance Presents Data on the RHA® Collection of Dermal Fillers at the 2021 Virtual Skin of Color Update Meeting

  9/10/2021

  Revance Therapeutics, Inc. today announced that its data will be featured during the 2021 Virtual Skin of Color Update meeting, taking place September 10-12, 2021.

• Revance to Participate in the Wells Fargo Securities Healthcare Conference - Sep 02, 2021

  9/2/2021

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will participate in the Wells Fargo Securities Healthcare Conference, a fully virtual management access conference, taking place September 9-10.

• Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery

  9/1/2021

  Revance Announces Publication of Results on Static Glabellar Lines With Repeated Treatment of DaxibotulinumtoxinA for Injection From the SAKURA Clinical Program in Dermatologic Surgery

• Revance Reports Second Quarter 2021 Financial Results, Provides Corporate Update

  8/5/2021

  Revance Therapeutics, Inc.Revance Therapeutics, Inc.Revance Therapeutics, Inc.Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

• Revance to Release Second Quarter 2021 Financial Results on Thursday, August 5, 2021

  7/29/2021

  Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company will release second quarter 2021 financial results on Thursday, August 5, 2021, after the close of market.